comparemela.com

Latest Breaking News On - Arvind dasari - Page 1 : comparemela.com

Selecting Optimal 3L Colorectal Cancer Treatment

Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.

FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC

For patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival.

Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC

Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
douglas-budget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from douglas-budget.com Daily Mail and Mail on Sunday newspapers.

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.